Roth Capital analyst Boobalan Pachaiyappan initiated coverage of PolyPid (PYPD) with a Buy rating and $9 price target The firm says its optimism on the shares is driven by D-PLEX100’s utility in curbing surgical site infection, particularly in patients undergoing colorectal cancer surgery. The company’s current cash position and potential near-term dilution could be balanced by D-PLEX100’s new drug application filing in the first half of 2026 and sales potential of over $800M in 2035, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYPD:
- PolyPid’s D-PLEX100 and PLEX Technology: A Promising Buy Amidst Upcoming Phase 3 SHIELD II Trial
- PolyPid assumed with a Buy at H.C. Wainwright
- PolyPid Expands Share Option Plan to Boost Stakeholder Engagement
- PolyPid Announces Leadership Changes Ahead of June 2025 Shareholder Meeting
- PolyPid Ltd. Earnings Call: Progress and Challenges